Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS
January 26, 2023 14:05 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases
January 06, 2023 14:50 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction
March 22, 2022 05:00 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members
February 17, 2022 17:42 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022
January 24, 2022 15:52 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium
October 29, 2021 15:44 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases...
Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response
September 28, 2021 11:17 ET
|
BioAegis Therapeutics
This biological phenomenon, quorum sensing in macrophages, regulates the transition of cells from inflammatory to healing phenotype. NORTH BRUNSWICK, New Jersey, Sept. 28, 2021 (GLOBE NEWSWIRE) --...
BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient
August 27, 2021 12:46 ET
|
BioAegis Therapeutics
Gelsolin immunomodulator treatment associated with patient’s rapid recovery. NORTH BRUNSWICK, N.J., Aug. 27, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year® 2021 New Jersey Award Finalist
June 04, 2021 13:00 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...